Menu
In order to grow and develop as people, as professionals, and as a company, we find it essential to contribute to the academic progress
Our publications
Below we provide links to posters and publications by Pharmetheus affiliates in chronological order. More complete publication records for Pharmetheus team members can be found in connection to the individual biographies.
Authors claiming Pharmetheus affiliation for the specific publication are highlighted with bold text. Please note that access to some publications may require a subscription.
2019
Lippert J, Burghaus R, Edginton A, Frechen S, Karlsson M, Kovar A, Lehr T, Milligan P, Nock V, Ramusovic S, Riggs M, Schaller S, Schlender J, Schmidt S, Sevestre M, Sjögren E, Solodenko J, Staab A, Teutonico D
Open Systems Pharmacology Community-An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical Sciences. (2019)
CPT Pharmacometrics Syst Pharmacol. 2019 Dec;8(12):878-882
Schoemaker R, Nayak S, Harnisch LO, Karlsson MO; VISTA-ICH Collaboration
Modeling and simulation of the modified Rankin Scale and National Institutes of Health Stroke Scale neurological endpoints in intracerebral hemorrhage. (2019)
J Pharmacokinet Pharmacodyn. 2019 Oct;46(5):473-484
Sargentini L, Hansson E, Bergstrand M, Callewaert F, Sousa R.
Effect of plasma exchange on the pharmacokinetics and pharmacodynamics of Caplacizumab, PS1487.
HemaSphere: June 2019 – Volume 3 – Issue S1 – p 685.
Sargentini L, Hansson E, Bergstrand M, Callewaert F, Sousa R.
Caplacizumab model-based dosing recommendations in pediatric patients with acquired thrombotic thrombocytopenic purpura, PB2249.
HemaSphere: June 2019 – Volume 3 – Issue S1 – p 1007.
Brekkan A, Lopez-Lazaro L, Plan EL, Nyberg J, Kankanwadi S, Karlsson MO
Sensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity Studies. (2019)
AAPS J. 2019 Jul 8;21(5):85.
Bergstrand M, Hansson E, Sargentini-Maier L
Caplacizumab Dosing Rational in aTTP Patients Supported by Mechanism Based PKPD Modelling. (2019)
PAGE 28 (2019) Abstr 8800
Kristoffersson A, Röshammar D, Plan EL
Assessment of expected drug exposure relative maximum safety limits in early phase studies. (2019)
PAGE 28 (2019) Abstr 9159
Brekkan A, Lopez-Lazaro L, Plan EL, Acharya C, Yngman G, Nyberg J, Hooker AC, Kankanwadi S, Karlsson MO
Model based support to biosimilarity assessment planning – A case study of pegfilgrastim. (2019)
PAGE 28 (2019) Abstr 9166
Nyberg J, Karlsson MO, Jonsson EN
Implicit and efficient handling of missing covariate information using full random effects modelling. (2019)
PAGE 28 (2019) Abstr 9181
Sjögren E, Jonsson EN
A PBPK Framework to Predict Drug Exposure in Malnourished Children. (2019)
PAGE 28 (2019) Abstr 8968
Sarr C, Magnusson MO, Vajjah P, Zamacona M
Population PK and PASI exposure-response modelling for Certolizumab pegol in patients with chronic plaque psoriasis. (2019)
PAGE 28 (2019) Abstr 9118
Nyberg J, Jonsson EN, Karlsson MO, Häggström J, members of the HBGDki Community
Properties of the full random effect modelling approach with missing covariates. (2019)
Preprint, doi: https://doi.org/10.1101/656470
Heimbach T, Suarez-Sharp S, Kakhi M, Holmstock N, Olivares-Morales A, Pepin X, Sjögren E, Tsakalozou E, Seo P, Li M, Zhang X, Lin HP, Montague T, Mitra A, Morris D, Patel N, Kesisoglou F
Dissolution and Translational Modeling Strategies Toward Establishing an In Vitro-In Vivo Link-a Workshop Summary Report. (2019)
AAPS J. 2019 Feb 11;21(2):29.
Netterberg I, Li CC, Molinero L, Budha N, Sukumaran S, Stroh M., Jonsson EN, Friberg LE
A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab-Treated non-small Cell Lung Cancer Patients. (2019)
Clin Pharmacol Ther. 2019 Feb;105(2):486-495.
2018
Guiastrennec B, Sonne DP, Bergstrand M, Vilsbøll T, Knop FK, Karlsson MO
Model-Based Prediction of Plasma Concentration and Enterohepatic Circulation of Total Bile Acids in Humans. (2018)
CPT Pharmacometrics Syst Pharmacol. 2018 Sep;7(9):603-612.
Terranova N, Smith MK, Nordgren R, Comets E, Lavielle M, Harling K, Hooker AC, Sarr C, Mentré F, Yvon F, Swat MJ
The Standard Output: A Tool-Agnostic Modeling Storage Format. (2018)
CPT Pharmacometrics Syst Pharmacol. 2018 Sep;7(9):543-546.
Suarez-Sharp S, Cohen M, Kesisoglou F, Abend A, Marroum P, Delvadia P, Kotzagiorgis E, Li M, Nordmark A, Bandi N, Sjögren E, Babiskin A, Heimbach T, Kijima S, Mandula H, Raines K, Seo P, Zhang X
Applications of Clinically Relevant Dissolution Testing: Workshop Summary Report. (2018)
AAPS J. 2018 Aug 27;20(6):93.
Brekkan A, Lopez-Lazaro L, Yngman G, Plan EL, Acharya C, Hooker AC, Kankanwadi S, Karlsson MO
A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim.
(2018) AAPS J. 2018 Aug 15;20(5):91
Jonsson EN, Harling K
Increasing the efficiency of the covariate search algorithm in the SCM. (2018)
PAGE 27 (2018) Abstr 8429
Kantasiripitak W, Sjögren E, Magnusson MO
Bridging physiologically based pharmacokinetic (PBPK) and population pharmacokinetic (PopPK) analyses in paediatric drug development: A case study based on intravenous esomeprazole. (2018)
PAGE 27 (2018) Abstr 8635
Rasmussen CH, Smith MK, Ito K, Sundararajan V, Magnusson MO, Jonsson NE, Fostvedt L, Burger P, McFadyen L, Tensfeldt TG, Nicholas T
PharmTeX: a LaTeX-Based Open-Source Platform for Automated Reporting Workflow. (2018)
AAPS J. 2018 Mar 16;20(3):52
2017
Friberg Hietala S, Manolis E, Musuamba F T
A Regulatory View on Dose Finding Studies and on the Value of Dose-Exposure-Response Analysis. (2017)
In O’Quigley J., Iasonos A., Bornkamp B., (Eds.), Handbook of Methods for Designing, Monitoring, and Analyzing Dose-Finding Trials. Boca Raton FL:CRC Press
Magnusson MO, Samtani MN, Plan EL, Jonsson EN, Rossenu S, Vermeulen A, Russu A
Dosing and Switching Strategies for Paliperidone Palmitate 3-Month ormulation in Patients with Schizophrenia Based on Population PharmacokineticModeling and Simulation, and Clinical Trial Data. (2017)
CNS Drugs.
Dosne AG, Bergstrand M, Karlsson MO
An Automated Sampling Importance Resampling Procedure for Estimating Parameter Uncertainty. (2017)
Clin. Pharmacol. Ther., 101: S5–S99
Conrado DJ, Karlsson MO, Romero K, Sarr C, Wilkins JJ
Open innovation: Towards sharing of data, models and workflows. (2017)
Eur J Pharm Sci. 2017 Nov 15;109S:S65-S71
Yngman G, Nyberg J, Jonsson EN, Karlsson MO
Practical considerations for using the full random effects modeling (FREM) approach to covariate modeling.
PAGE 26 (2017) Abstr 7365
Röshammar D, Bergstrand M, Andersson T, Storey R.F, Hamrén B
Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction
. (2017)
Int J Clin Pharmacol Ther. Jan 30.
Nguyen T, Mouksassi M-S, Holford N, Al-Huniti N, Freedman I, Hooker A, John J, Karlsson M, Mould D, Pérez Ruixo J, Plan EL, Savic R, van Hasselt J, Weber B, Zhou C, Comets E, Mentré F for the Model Evaluation Group of the International Society of Pharmacometrics (ISoP)
Best Practice Committee, Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics. (2017)
CPT Pharmacometrics Syst. Pharmacol.
2016
Slejko JF, Willke RJ, Ribbing J, Milligan P
Translating Pharmacometrics to a Pharmacoeconomic Model of COPD. (2016)
Value Health. 2016 Dec;19(8):1026-1032
Röshammar D, Nyberg J, Andersson T, Stanski D, Storey RF, Hamrén B
Exposure-Response Analyses Supporting Ticagrelor Dosing Recommendation in Patients With Prior Myocardial Infarction. (2016)
J Clin Pharmacol. Nov.
Magnusson MO, Samtani MN, Plan EL, Jonsson EN, Rossenu S, Vermeulen A, Russu A
Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia. (2016)
Clin Pharmacokinet., 56: 421
van Schaick E, Benninga MA, Levine A, Magnusson MO, Troy S
Development of apopulation pharmacokinetic model of prucalopride in children with functionalconstipation. (2016)
Pharma Res Per, 4(4), e00236.
Magnusson MO
Application of a multi-criteria decision analysis model in the dose selection of combination therapy for overactive bladder. (2016)
WCoP, Talk: Symposium 5, Pharmacometric approaches to optimize dose selection Abstr 125.
Jonsson EN, Xie R, Marshall SF, Arends RH
Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain. (2016)
Br J Clin Pharmacol. Apr;81(4):688-99
Jonsson EN, Nyberg J, Häggström J, Lifecycle Auxology & Neurocognitive Development team, representing the Healthy Birth, Growth and Development knowledge integration (HBGDki) community
Determinants for physical growth patterns in low- and middle-income countries. (2016)
PAGE 25 Abstr 5844, Talk: Growth.
Magnusson MO, Plan EL, Remy A, König M, Aigner S, Braun V, Zipp D, Zhou X, Wolter R, Schüttrumpf J, Wartenberg-Demand A, Dälken B, Rharbaoui F
Population PKPD Analysis of CD4 and ACR Response after SC Administration of Tregalizumab to Patients with Rheumatoid Arthritis. (2016)
PAGE 25 Abstr 57
2015
Hamberg AK, Hellman J, Dahlberg J, Jonsson EN, Wadelius M
A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children. (2015)
BMC Med Inform Decis Mak. Feb 7;15:7
Khariton T, Jonsson EN, Bergstrand M, Carrothers TJ, Ghahramani P
Population Pharmacokinetic (PPK) Modeling of Vilazodone in Adolescent Patients with Major Depressive Disorder (MDD). (2015)
J Pharmacokinet Pharmacodyn 42(Suppl 1): 11
Khariton T, Jonsson EN, Bergstrand M, Carrothers TJ, Ghahramani P
PKPD Modeling of Vilazodone (VLZ) in Adult Patients with Generalized Anxiety Disorder (GAD). (2015)
J Pharmacokinet Pharmacodyn 42(Suppl 1): 11
Magnusson MO, Samtani MN, Plan EL, Jonsson EN, Rossenu S, Vermeulen A.
Population Pharmacokinetic Simulations of Two Paliperidone Palmitate Formulations. (2015)
PAGE 24 Abstr 3643.
Magnusson MO, Samtani MN, Plan EL, Jonsson EN, Rossenu S, Vermeulen A
Population Pharmacokinetic Modeling of Paliperidone Palmitate 3-Month Formulation. (2015)
PAGE 24 Abstr 3408.
2014
Plan EL
Modeling and simulation of count data. (2014)
CPT Pharmacometrics Syst.Pharmacol. 3, e129.
Khariton T, Bergstrand M, Plan EL, Ghahramani P
A Population PKPD Model for Changes in Sexual Function Questionnaire (CSFQ) in Patients with Major Depressive Disorder (MDD) Treated with Vilazodone or Placebo. (2014)
J Pharmacokinet Pharmacodyn 41(Suppl 1): 7
Hamberg AK, Wadelius M, Friberg LE, Biss TT, Kamali F, Jonsson EN
Characterizing variability in warfarin dose requirements in children using modelling and simulation. (2014)
Br J Clin Pharmacol. Jul;78(1):158-69
Magnusson MO, Jonsson EN, Chen CL, Carrothers T, Ghahramani P
A Population PK/PD Analysis of Nebivolol and Valsartan Combination Therapy. (2014)
PAGE 23 Abstr 3162.
Jonsson EN., Magnusson MO, Chen CL, Carrothers T, Ghahramani P
A Population PK Analysis of Nebivolol and Valsartan in Combination Therapy. (2014)
PAGE 23 Abstr 3150.
2013
Justin J. Wilkins JJ, Jonsson EN
Reproducible Pharmacometrics. (2013)
PAGE 22 Abstr 2774 Oral: Tutorial